Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines

Human Gene Therapy MethodsVol. 28, No. 6 Research ArticlesOpen AccessScalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell LinesAziza P. Manceur, Howard Kim, Vanja Misic, Nadejda Andreev, July Dorion-Thibaudeau, Stéphane Lanthier, Alice Bernier, Sonia Tremblay, Anne-Marie Gélinas, Sophie Broussau, Rénald Gilbert, and Sven AnsorgeAziza P. ManceurHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, Howard KimBridGE, Centre for Commercialization of Regenerative Medicine, Toronto, Canada.Search for more papers by this author, Vanja MisicBridGE, Centre for Commercialization of Regenerative Medicine, Toronto, Canada.Search for more papers by this author, Nadejda AndreevBridGE, Centre for Commercialization of Regenerative Medicine, Toronto, Canada.Search for more papers by this author, July Dorion-ThibaudeauHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, Stéphane LanthierHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, Alice BernierHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, Sonia TremblayHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, Anne-Marie GélinasHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, Sophie BroussauHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, Rénald GilbertHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this author, and Sven AnsorgeHuman Health Therapeutics, National Research Council Canada, Montreal, CanadaSearch for more papers by this authorPublished Online:1 Dec 2017https://doi.org/10.1089/hgtb.2017.086AboutSectionsView articleSupplemental MaterialPDF/EPUBView Supplemental Data Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byPackaging cells for lentiviral vectors generated using the cumate and coumermycin gene induction systems and nanowell single-cell cloningMolecular Therapy - Methods & Clinical Development, Vol. 29Process intensification strategies toward cell culture‐based high‐yield production of a fusogenic oncolytic virus21 February 2023 | Biotechnology and Bioengineering, Vol. 35Enhancing recombinant protein and viral vector production in mammalian cells by targeting the YTHDF readers of N6 ‐methyladenosine in mRNA5 February 2023 | Biotechnology Journal, Vol. 592Process for production of chimeric antigen receptor-transducing lentivirus particles using infection with replicon particles containing self-replicating RNAsBiochemical Engineering Journal, Vol. 191Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platformVaccine, Vol. 41, No. 9Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing30 November 2022 | Molecular Biotechnology, Vol. 12Culture media selection and feeding strategy for high titer production of a lentiviral vector by stable producer clones cultivated at high cell density27 June 2022 | Bioprocess and Biosystems Engineering, Vol. 45, No. 8Mitigating Host Burden of Genetic Circuits by Engineering Autonegatively Regulated Parts and Improving Functional Prediction30 June 2022 | ACS Synthetic Biology, Vol. 11, No. 7Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing14 June 2022 | Frontiers in Bioengineering and Biotechnology, Vol. 10Plasma-Enabled Smart Nanoexosome Platform as Emerging Immunopathogenesis for Clinical Viral Infection13 May 2022 | Pharmaceutics, Vol. 14, No. 5Viral Generation, Packaging, and Transduction on a Digital Microfluidic Platform22 February 2022 | Analytical Chemistry, Vol. 94, No. 9Cancer Gene Therapy: Development and Production of Lentiviral Vectors for Gene Therapy23 June 2022HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors13 December 2021 | Frontiers in Bioengineering and Biotechnology, Vol. 9Use of lentiviral vectors in vaccination11 October 2021 | Expert Review of Vaccines, Vol. 20, No. 12A high cell density perfusion process for Modified Vaccinia virus Ankara production: Process integration with inline DNA digestion and cost analysis23 September 2021 | Biotechnology and Bioengineering, Vol. 118, No. 12Gene therapy process change evaluation framework: Transient transfection and stable producer cell line comparisonBiochemical Engineering Journal, Vol. 176Viral vector platforms within the gene therapy landscape8 February 2021 | Signal Transduction and Targeted Therapy, Vol. 6, No. 1Novel method for quantifying cells on carriers and its demonstration during SARS‐2 vaccine development15 June 2021 | Biotechnology and Bioengineering, Vol. 118, No. 10Construction of a eukaryotic expression system with stable and secretory expression of mycobacterium tuberculosis 38 kDa protein14 September 2021 | World Journal of Microbiology and Biotechnology, Vol. 37, No. 10The Engineered MARCH8-Resistant Vesicular Stomatitis Virus Glycoprotein Enhances Lentiviral Vector Transduction Fengwen Xu, Xiaoman Liu, Di Zhang, Fei Zhao, Zhangling Fan, Siqi Hu, Shan Mei, Yu Huang, Hong Sun, Liang Wei, Li Guo, Jianwei Wang, Shan Cen, Chen Liang, and Fei Guo23 September 2021 | Human Gene Therapy, Vol. 32, No. 17-18Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives2 August 2021 | Viruses, Vol. 13, No. 8The transformative potential of HSC gene therapy as a genetic medicine26 May 2021 | Gene Therapy, Vol. 11Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value Delfi Krishna, Laure Rittié, Hoang Tran, Xuan Zheng, Chia-en Chen-Rogers, Amanda McGillivray, Timothy Clay, Amol Ketkar, and Joseph Tarnowski17 May 2021 | Human Gene Therapy, Vol. 32, No. 9-10Characterization of Extracellular Vesicles Secreted in Lentiviral Producing HEK293SF Cell Cultures29 April 2021 | Viruses, Vol. 13, No. 5Lentiviral vector bioprocess economics for cell and gene therapy commercializationBiochemical Engineering Journal, Vol. 167Lentiviral Vector Bioprocessing9 February 2021 | Viruses, Vol. 13, No. 2Viral Vectors for COVID-19 Vaccine Development19 February 2021 | Viruses, Vol. 13, No. 2Advances in Lentivirus Purification8 December 2020 | Biotechnology Journal, Vol. 16, No. 1Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production8 September 2020 | Biotechnology Journal, Vol. 16, No. 1A new simplified clarification approach for lentiviral vectors using diatomaceous earth improves throughput and safe handlingJournal of Biotechnology, Vol. 326Expression Cassette Design and Regulation of Transgene Expression6 July 2021 | International Ophthalmology Clinics, Vol. 61, No. 3Multivariate data analysis in cell gene therapy manufacturingBiotechnology Advances, Vol. 45Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed BioreactorMolecular Therapy - Methods & Clinical Development, Vol. 19Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges3 November 2020 | Pharmaceutics, Vol. 12, No. 11Engineering a Synthesis-Friendly Constitutive Promoter for Mammalian Cell Expression14 September 2020 | ACS Synthetic Biology, Vol. 9, No. 10Rapid In-Process Monitoring of Lentiviral Vector Particles by High-Performance Liquid ChromatographyMolecular Therapy - Methods & Clinical Development, Vol. 18Transposon vector-mediated stable gene transfer for the accelerated establishment of recombinant mammalian cell pools allowing for high-yield production of biologics22 April 2020 | Biotechnology Letters, Vol. 42, No. 7Performance of an acoustic settler versus a hollow fiber–based ATF technology for influenza virus production in perfusion15 April 2020 | Applied Microbiology and Biotechnology, Vol. 104, No. 11Assessment and streamlined preparation of low-cytotoxicity lentiviral vectors for mobilized human hematopoietic stem cell transductionExperimental Hematology, Vol. 86Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free MediaMolecular Therapy - Methods & Clinical Development, Vol. 17Current challenges in biotherapeutic particles manufacturing27 November 2019 | Expert Opinion on Biological Therapy, Vol. 20, No. 5Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production Hanna M. Leinonen, Saana Lepola, Eevi M. Lipponen, Tommi Heikura, Tiina Koponen, Nigel Parker, Seppo Ylä-Herttuala, and Hanna P. Lesch17 March 2020 | Human Gene Therapy, Vol. 31, No. 5-6Lentiviral Vector Production in Suspension Culture Using Serum-Free Medium for the Transduction of CAR-T Cells10 November 2019Gene therapyImpact of dextran sulfate in culture media on titration of vesicular stomatitis virusJournal of Virological Methods, Vol. 275Titration methods for rVSV-based vaccine manufacturingMethodsX, Vol. 7Establishment of stable Vero cell lines expressing TMPRSS2 and MSPL: A useful tool for propagating porcine epidemic diarrhea virus in the absence of exogenous trypsin29 May 2020 | Virulence, Vol. 11, No. 1Pharmaceutics, Vol. 12, No. 6Lentiviral Vector Purification Using Nanofiber Ion-Exchange ChromatographyMolecular Therapy - Methods & Clinical Development, Vol. 15Identification of novel breakpoints for locus- and region-specific translocations in 293 cells by molecular cytogenetics before and after irradiation22 July 2019 | Scientific Reports, Vol. 9, No. 1Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systemsVaccine, Vol. 37, No. 47Gene Therapy: Principles and Clinical PotentialProduction of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cellsVaccine, Vol. 37, No. 44Lentiviral Vectors Come of Age? Hurdles and Challenges in Scaling Up Manufacture19 June 2019Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System Alexandra McCarron, Martin Donnelley, Chantelle McIntyre, and David Parsons13 June 2019 | Human Gene Therapy Methods, Vol. 30, No. 3RNA Viruses as Tools in Gene Therapy and Vaccine Development1 March 2019 | Genes, Vol. 10, No. 3Optimization of production of vesicular stomatitis virus (VSV) in suspension serum-free culture medium at high cell densityJournal of Biotechnology, Vol. 289New technologies in gene therapy for inducing immune tolerance in hemophilia A3 November 2018 | Expert Review of Clinical Immunology, Vol. 14, No. 12Continuous manufacturing of viral particlesCurrent Opinion in Chemical Engineering, Vol. 22 Volume 28Issue 6Dec 2017 InformationCopyright 2017, Mary Ann Liebert, Inc.To cite this article:Aziza P. Manceur, Howard Kim, Vanja Misic, Nadejda Andreev, July Dorion-Thibaudeau, Stéphane Lanthier, Alice Bernier, Sonia Tremblay, Anne-Marie Gélinas, Sophie Broussau, Rénald Gilbert, and Sven Ansorge.Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.Human Gene Therapy Methods.Dec 2017.330-339.http://doi.org/10.1089/hgtb.2017.086creative commons licensePublished in Volume: 28 Issue 6: December 1, 2017Online Ahead of Print:November 21, 2017Online Ahead of Editing: August 21, 2017Keywordslentiviral vectorstable producerHEK293SFperfusionbioprocessingPDF download